<DOC>
	<DOCNO>NCT00687700</DOCNO>
	<brief_summary>Study investigate pharmacodynamics dual pharmacophore combination GSK961081 Propanolol use give total effect bronchodilation .</brief_summary>
	<brief_title>A Study Investigate Pharmacology Dual Pharmacophore Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Healthy adult male age 18 50 year . Body mass index within range 1929.9 kg/m2 . FEV1 ≥ 80 % predict FEV1/ Forced Vital Capacity ( FVC ) ratio ≥ 0.7 Signed date write informed consent obtain subject The subject able understand comply protocol requirement , instruction protocolstated restriction . The subject increase sGAW ≥15 % predose baseline within 2 h administration 400 µg salbutamol MDI inhaler screen 3 month screen . The subject increase sGAW ≥25 % predose baseline within 2 h follow 80 µg ipratropium bromide screen 3 month screen . Subjects current nonsmoker use tobacco product 6month period precede screen visit pack history ≥ 10 pack year . Any clinically relevant abnormality identify screen medical assessment ( physical examination/medical history ) , clinical laboratory test , ECG ( 12lead Holter ) . A history respiratory disease ( i.e . history asthmatic symptom ) . Clinically significant abnormal 12 lead ECG A subject ipratropium bromide , salbutamol propranolol contraindicate . A supine blood pressure persistently high 140/90 millimetre mercury ( mmHg ) screening . A supine mean heart rate outside range 4590 beat per minute ( bpm ) screening . The subject donate unit blood within 56 day intend donate within 56 day complete study . The subject currently take regular ( course ) medication whether prescribed ( exception contraceptive , include vitamin herbal remedy St John 's Wort . The subject use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( ever longer ) prior first dose study medication , unless opinion Investigator medical monitor medication interfere study procedure compromise subject safety . The subject participate clinical study New Chemical Entity ( NCE ) within past 3 month . Exposure four new chemical entity within 12 month prior first dose day . The subject infect Hepatitis B , Hepatitis C , HIV virus . The subject positive prestudy urine cotinine/ breath carbon monoxide test , urine drug/urine alcohol screen . A history regular alcohol consumption exceed weekly intake alcohol great 28 unit male , average daily intake great 4 unit . Are unable use inhaler correctly . The subject history drug allergy , , opinion Investigator , contraindicate participation . The subject low respiratory tract infection within 4 week study start . Subject unable perform sGAW measurement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>propranolol</keyword>
	<keyword>B2-agonist ,</keyword>
	<keyword>B-antagonist ,</keyword>
</DOC>